Tumor microenvironment and immunology of cholangiocarcinoma

Cadamuro, Massimiliano; Fabris, Luca; Zhang, Xuchen; Strazzabosco, Mario

doi:10.20517/2394-5079.2021.140

Cited by 3 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Observational investigations, combining CTLA-4 inhibitors (i.e., Tremelimumab) and TACE for patients with advanced HCC and hepatitis C, have exhibited a resultant reduction in viral load and an increase in intratumoral CD8+ cells from tumor biopsies [93]. A phase 1 clinical trial is underway using Tremelinumab in combination with radiofrequency ablation or TACE [94]. PD-1 inhibitors, such as Lenvatinib, are also being explored for unresectable HCC.…”

Section: Combining Image-guided Therapies With Immunotherapymentioning

confidence: 99%

Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors

Criss

Makary

2023

Biology

View full text Add to dashboard Cite

Primary liver cancer is the leading cause of cancer-related deaths worldwide. with incidences predicted to rise over the next several decades. Locoregional therapies, such as radiofrequency or microwave ablation, are described as image-guided percutaneous procedures, which offer either a curative intent for early-stage hepatocellular carcinoma or bridging/downstaging for surgical resection or transplantation. Catheter-driven locoregional therapies, such as transarterial chemoembolization and radioembolization, induce tumor hypoxia, can be palliative, and improve survival for early-to-intermediate hepatocellular carcinoma and unresectable intrahepatic cholangiocarcinoma. Herein, we provide a comprehensive overview of the antineoplastic mechanisms underpinning locoregional therapies, different treatment approaches, and the current state of the literature for the efficacy of locoregional therapies for primary liver cancer. We also discuss emerging advancements, such as the adjuvant use of immunotherapies and molecular targeting agents with locoregional therapy, for the treatment of primary liver cancer.

show abstract

Section: Combining Image-guided Therapies With Immunotherapymentioning

confidence: 99%

Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors

Criss

Makary

2023

Biology

View full text Add to dashboard Cite

show abstract

“…Tumor microenvironment (TME), is mainly composed of tumor cells, and surrounding immune and in ammatory cells, cancer-associated broblasts, and nearby interstitial tissues, as well as microvessels, various cytokines and chemokines [4]. It is a complex integrated system that tumor cells and their microenvironment interact with each other to promote the occurrence of tumors.…”

Section: Introductionmentioning

confidence: 99%

P3H1 as a novel prognostic biomarker correlates with immune infiltrate

Wu,

You,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Prolyl 3-hydroxylase 1(P3H1), a member of the collagen prolyl hydroxylase family, plays an important role in the development and progression of malignant tumors. However, expression and prognostic value of P3H1 and its correlation with tumor immunity in some cancer remain unclear. Methods We identified transcription level in the P3H1 gene by searching the GEPIA2.0 and ULCAN databases, and then analyzed the relationship between gene expression and prognosis in each tumor using survival R package, and computed the log-rank P value and hazard ratio (HR) with 95% confidence intervals (95% CI). Specifically, we used the oncomine and databases to further explore the relationship between P3H1 expression and the cancer prognosis. Moreover, we further investigated the role of P3H1 in tumor immunology using TIMER2.0 database. The relationship between the expression of this gene and TMB, NEO and MSI were also evaluated. More importantly, we performed signaling pathway enrichment analysis by KEGG and GO. Then, anticancer drug sensitivity analysis was performed using the pRRophetic R package. Finally, ELISA analysis was performed to compare the P3H1 serum level both the patients of COAD and healthy subjects. Results P3H1 was abnormally overexpressed in multiply tumors and distinct associations exist between P3H1 expression and prognosis of tumor patients by analysis online data. Moreover, we identified a strong correlation between P3H1 expression and immune checkpoint gene expression in diverse cancers. High expression of P3H1 was correlated with the immune infiltrated in COAD. Remarkably, a positive correlation between P3H1 expression and tumor mutation burden and neoantigen in colon adenocarcinoma (COAD) was observed. Furthermore, P3H1 was involved in the extracellular matrix organization and immune-related pathways in COAD. In addition, drug sensitivity analysis revealed that high P3H1 group has higher sensitivity in diverse drug for the therapy of COAD compared to low P3H1 group. Finally, the serum level of P3H1 was much higher in patients with COAD than in control subjects, indicating a link between P3H1 and COAD. Conclusion Our study provides a comprehensive insight for revealing the significant role of P3H1 in the expression, survival, tumor immune, microenvironment of human cancers, and anticancer drug sensitivity analysis of COAD.

show abstract

Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response

Shao,

Zhao,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundLiver hepatocellular carcinoma (LIHC) ranks as the foremost cause of cancer-related deaths worldwide, and its early detection poses considerable challenges. Current prognostic indicators, including alpha-fetoprotein, have notable limitations in their clinical utility, thereby underscoring the necessity for discovering new biomarkers to improve early diagnosis and enable personalized treatment options.MethodThis investigation employed single-cell analysis techniques to identify stem cell-associated genes and assess their prognostic significance for LIHC patients, as well as the efficacy of immunotherapy, utilizing nonnegative matrix factorization (NMF) cluster analysis. A diagnostic model for LIHC was developed and validated through multiple datasets and various machine learning clustering methods. The XGBOOST algorithm identified MRPL17 as the most significant prognostic gene among those associated with stem cells. Additionally, the research explores the relationship between MRPL17 expression and immune cell infiltration. Immunofluorescence staining of LIHC tissue samples was conducted to evaluate the expression and prognostic value of MRPL17, as well as its correlation with KI67.ResultsThrough single-cell analysis, this study identified 14 essential stem cell-related genes, highlighting their significance in the diagnosis, prognostication, and potential treatment strategies for LIHC patients. Various machine learning algorithms indicated that MRPL17 is particularly associated with patient prognosis and responses to immunotherapy. Furthermore, experimental results demonstrate that MRPL17 is upregulated in LIHC and correlates with poor prognosis, as well as positively correlating with KI67.ConclusionCancer stem cells are pivotal in the mechanisms of immune evasion within the tumor microenvironment and have a substantial impact on treatment results. This study experimentally validated MRPL17 as a promising prognostic biomarker, emphasizing the need to target liver cancer stem cells to improve patient prognosis and enhance treatment effectiveness.

show abstract

Tumor microenvironment and immunology of cholangiocarcinoma

Cited by 3 publications

References 100 publications

Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors

Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors

P3H1 as a novel prognostic biomarker correlates with immune infiltrate

Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response

Contact Info

Product

Resources

About